These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36119229)

  • 41. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
    Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
    PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015-2018.
    Hu R; Peng S; Liu Y; Tang F; Wang Z; Zhang L; Gao J; Guo H
    BMC Public Health; 2021 Jul; 21(1):1338. PubMed ID: 34229643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future.
    Hamayoun M; Abdulrazak I; Farid M; Malik MR; Mohamud MF
    IJID Reg; 2022 Sep; 4():47-52. PubMed ID: 35720961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Artificial Intelligence-Enabled Social Media Analysis for Pharmacovigilance of COVID-19 Vaccinations in the United Kingdom: Observational Study.
    Hussain Z; Sheikh Z; Tahir A; Dashtipour K; Gogate M; Sheikh A; Hussain A
    JMIR Public Health Surveill; 2022 May; 8(5):e32543. PubMed ID: 35144240
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring the safety of influenza A/H1N1 pandemic and seasonal vaccines in Morocco.
    Tebaa A; Benkirane R; Alj L; Cherkaoui I; Soulaymani-Bencheikh R
    Ther Adv Vaccines Immunother; 2022; 10():25151355221088157. PubMed ID: 35372783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.
    Duijster JW; Lieber T; Pacelli S; Van Balveren L; Ruijs LS; Raethke M; Kant A; Van Hunsel F
    Front Immunol; 2023; 14():1078736. PubMed ID: 36793715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
    Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India.
    Jha A; Kumar P; Goel SK; Bharatwal AA; Dhamnetiya D; Singh S; Jha RP
    J Family Med Prim Care; 2024 Jan; 13(1):298-310. PubMed ID: 38482279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse events following immunization (AEFI): COVID-19 vaccine dose and characteristics in Central Java, Indonesia.
    Wahyudi F; Nugraheni A; Margawati A; Pramono D; Adespin DA; Nugroho TW; Pramana C
    Germs; 2023 Mar; 13(1):40-49. PubMed ID: 38023961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
    Masuka JT; Khoza S
    BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes following COVID-19 vaccination and associated factors among healthcare professionals in Oromia region, Ethiopia.
    Terefa DR; Shama AT; Tekle E
    Hum Vaccin Immunother; 2023 Dec; 19(1):2167901. PubMed ID: 36703523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imprecision in vaccine adverse event reporting and a methodological analysis of reporting systems to improve pharmacovigilance and public health.
    Inokuma Y; Kneller R
    Eur J Clin Pharmacol; 2023 Jul; 79(7):989-1002. PubMed ID: 37249640
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Manifestations of adverse events post Sinovac vaccine immunization at Wirasakti Hospital, Kupang.
    Basri AH; Roga AU; Basri M; Tresno I; Lerik MCD
    J Public Health Afr; 2023 Apr; 14(4):1963. PubMed ID: 37347068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adherence to and early adverse events of COVID-19 vaccine in a cohort of 600 Italian breastfeeding and pregnant physicians.
    Montalti M; Guaraldi F; Di Valerio Z; Ragghianti B; Tedesco D; Mannucci E; Monami M; Gori D
    Hum Vaccin Immunother; 2022 Nov; 18(6):2106747. PubMed ID: 35944074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19 vaccine acceptance, hesitancy, and determinants among physicians in a university-based teaching hospital in Thailand.
    Sirikalyanpaiboon M; Ousirimaneechai K; Phannajit J; Pitisuttithum P; Jantarabenjakul W; Chaiteerakij R; Paitoonpong L
    BMC Infect Dis; 2021 Nov; 21(1):1174. PubMed ID: 34809607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A cohort event monitoring to determine the adverse events following administration of mouse brain derived, inactivated Japanese Encephalitis vaccine in an endemic district in Sri Lanka.
    De Alwis KN; Abeysinghe MR; Wickramesinghe AR; Wijesinghe PR
    Vaccine; 2014 Feb; 32(8):924-30. PubMed ID: 24406391
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Self-reported side effects of COVID-19 vaccines among health professions students in India.
    Majumder MAA; Bharatha A; Kumar S; Chatterjee M; Gupta S; Harewood H; Singh K; Johnson W; Rajasundaram A; Dutta SB; Prasad SV; Rahman S; Kabir R; Parsa AD; Gaur U; Rabbi AMF; Krishnamurthy K; Mohammad S; Chode V; Haque M; Campbell MH
    PeerJ; 2024; 12():e17083. PubMed ID: 38590705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.